Clinical Trial

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

Study acronym: PHANTOM
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated August 12, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity) and imaging time window of 64Cu-LNTH-1363S, and to compare its imaging biodistribution with FAP expression by IHC in patients with sarcomas or GIT cancers. The study will be conducted in 2 parts (Part 1 and Part 2).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2024-03-01; most recent amendment 2025-08-06.
Status change: Not Yet Recruiting → Recruiting 2024-10-17
Trial Details
NCT Number NCT06298916
Lead Sponsor Lantheus Medical Imaging
Conditions Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma
Enrollment 26 participants
Start Date 2025-08
Primary Completion 2025-11 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-08-12